Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease.

Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B, Johnson KB, St George JA, Johnson MR, Boucher RC.

J Pharmacol Exp Ther. 2008 Apr;325(1):77-88. doi: 10.1124/jpet.107.130443. Epub 2008 Jan 24.

PMID:
18218832
2.

Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.

Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR.

J Med Chem. 2006 Jul 13;49(14):4098-115.

PMID:
16821771
3.

Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.

Hirsh AJ, Sabater JR, Zamurs A, Smith RT, Paradiso AM, Hopkins S, Abraham WM, Boucher RC.

J Pharmacol Exp Ther. 2004 Dec;311(3):929-38. Epub 2004 Jul 23.

PMID:
15273255

Supplemental Content

Loading ...
Support Center